Exelixis Inc (EXEL)

Healthcare Pharmaceuticals & Medical Research Biotechnology & Medical Research

Track Share on 𝕏

Stock chart

Ticker: EXEL Exchange: NSM

Subscribe to get access to the transaction volume chart and in-chart transaction details

• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale

Past 90 days

Value bought

Value sold

Net insiders buying

Trades (buy and sell)

Company data

Subscribe to get access to the company description and key fundamental data (market cap, shares outstanding, dividend yield, % of shares held by insiders and more)

Download results

Abbreviations B: Buy, S: Sell, PP: Planned purchase, PS: Planned sale, O: Option / Other

Notification date	Transaction date	B/S Transaction type	Insider and/or position	Nb. shares Price Value	Number of shares	Price	Total value
2024-05-15	2024-05-13	PS Planned sale	WYSZOMIERSKI JACK L Non-Executive Director	1,000 -3.1% 21.37 100,000 USD	1,000 -3.1%	21.37	100,000 USD
2024-03-25	2024-03-21	PS Planned sale	Garber Alan M Non-Executive Director	19,205 -35.0% 24.01 461,112 USD	19,205 -35.0%	24.01	461,112 USD
2024-02-27	2024-02-23	S Sale	Haley Patrick J. EVP, Commercial Officer	47,020 -10.9% 21.45 1,008,579 USD	47,020 -10.9%	21.45	1,008,579 USD
2024-02-22	2024-02-21	B Purchase	JOHNSON DAVID EDWARD Non-Executive Director	190,000 +20.9% 20.70 3,932,734 USD	190,000 +20.9%	20.70	3,932,734 USD
2023-12-14	2023-12-14	PS Planned sale	Haley Patrick J. EVP, Commercial Officer	50,000 -14.0% 23.35 1,167,500 USD	50,000 -14.0%	23.35	1,167,500 USD
2023-12-14	2023-12-13	PS Planned sale	Hessekiel Jeffrey EVP, General Counsel & Sec Officer	25,000 -4.5% 23.01 575,250 USD	25,000 -4.5%	23.01	575,250 USD
2023-12-14	2023-12-12	PS Planned sale	Haley Patrick J. EVP, Commercial Officer	14,149 -4.4% 22.50 318,353 USD	14,149 -4.4%	22.50	318,353 USD
2023-12-04	2023-12-04	PS Planned sale	Hessekiel Jeffrey EVP, General Counsel & Sec Officer	25,000 -4.3% 22.06 551,500 USD	25,000 -4.3%	22.06	551,500 USD
2023-12-04	2023-11-30	PS Planned sale	Hessekiel Jeffrey EVP, General Counsel & Sec Officer	25,000 -4.1% 22.01 550,250 USD	25,000 -4.1%	22.01	550,250 USD
2023-11-29	2023-11-27	B Purchase	JOHNSON DAVID EDWARD Non-Executive Director	120,409 +15.2% 21.61 2,602,038 USD	120,409 +15.2%	21.61	2,602,038 USD
2023-11-29	2023-11-27	S Sale	JOHNSON DAVID EDWARD Non-Executive Director	120,409 -13.2% 21.61 2,602,038 USD	120,409 -13.2%	21.61	2,602,038 USD
2023-09-01	2023-08-30	PS Planned sale	Aftab Dana CSO/EVP Disc & Trans Research Officer	4,600 -1.1% 22.47 103,362 USD	4,600 -1.1%	22.47	103,362 USD
2023-08-07	2023-08-04	S Sale	Senner Christopher J. EVP and CFO Officer	60,000 -9.5% 20.68 1,240,800 USD	60,000 -9.5%	20.68	1,240,800 USD
2023-08-07	2023-08-03	S Sale	Senner Christopher J. EVP and CFO Officer	60,000 -9.5% 20.51 1,230,600 USD	60,000 -9.5%	20.51	1,230,600 USD
2023-08-07	2023-08-03	S Sale	Haley Patrick J. EVP, Commercial Officer	30,553 -9.7% 20.67 631,531 USD	30,553 -9.7%	20.67	631,531 USD
2023-08-03	2023-08-01	PS Planned sale	Hessekiel Jeffrey EVP, General Counsel & Sec Officer	55,710 -8.9% 19.63 1,093,587 USD	55,710 -8.9%	19.63	1,093,587 USD
2023-04-05	2023-04-05	PS Planned sale	Hessekiel Jeffrey EVP, General Counsel & Sec Officer	38,930 -6.3% 20.01 778,989 USD	38,930 -6.3%	20.01	778,989 USD
2023-03-14	2023-03-10	PS Planned sale	WYSZOMIERSKI JACK L Non-Executive Director	15,300 -4.6% 16.61 254,133 USD	15,300 -4.6%	16.61	254,133 USD
2023-03-03	2023-03-01	PS Planned sale	Hessekiel Jeffrey EVP, General Counsel & Sec Officer	77,860 -12.9% 17.13 1,333,742 USD	77,860 -12.9%	17.13	1,333,742 USD
2023-03-01	2023-02-28	S Sale	Aftab Dana CSO/EVP Disc & Trans Research Officer	82,490 -19.0% 17.50 1,443,575 USD	82,490 -19.0%	17.50	1,443,575 USD
2023-03-01	2023-02-27	S Sale	Aftab Dana CSO/EVP Disc & Trans Research Officer	10 -0.0% 17.50 175 USD	10 -0.0%	17.50	175 USD
2023-02-23	2023-02-21	PS Planned sale	Garber Alan M Non-Executive Director	40,000 -56.0% 17.49 699,600 USD	40,000 -56.0%	17.49	699,600 USD
2023-02-10	2023-02-09	S Sale	FELDBAUM CARL B Non-Executive Director	40,000 -68.1% 17.78 711,200 USD	40,000 -68.1%	17.78	711,200 USD
2023-02-08	2023-02-06	PS Planned sale	Haley Patrick J. EVP, Commercial Officer	25,000 -8.9% 17.37 434,250 USD	25,000 -8.9%	17.37	434,250 USD
2022-12-16	2022-12-15	PS Planned sale	Lamb Peter EVP, Scientific Strategy & CSO Officer	20,000 -4.6% 15.88 317,600 USD	20,000 -4.6%	15.88	317,600 USD
2022-12-01	2022-11-29	S Sale	POSTE GEORGE Non-Executive Director	40,000 -17.2% 16.68 667,200 USD	40,000 -17.2%	16.68	667,200 USD
2022-09-14	2022-09-12	PS Planned sale	Haley Patrick J. EVP, Commercial Officer	40,000 -13.3% 17.94 717,600 USD	40,000 -13.3%	17.94	717,600 USD
2022-06-01	2022-05-27	S Sale	Haley Patrick J. EVP, Commercial Officer	18,812 -7.3% 18.21 342,567 USD	18,812 -7.3%	18.21	342,567 USD
2022-11-17	2022-05-16	PS Planned sale	Hessekiel Jeffrey EVP, General Counsel & Sec Officer	18,000 -3.0% 20.07 361,260 USD	18,000 -3.0%	20.07	361,260 USD
2022-05-13	2022-05-12	S Sale	WILLSEY LANCE Non-Executive Director	40,000 -8.6% 19.65 786,000 USD	40,000 -8.6%	19.65	786,000 USD
2022-04-06	2022-04-04	PS Planned sale	WYSZOMIERSKI JACK L Non-Executive Director	6,696 -2.4% 23.00 154,008 USD	6,696 -2.4%	23.00	154,008 USD
2022-04-04	2022-04-01	PS Planned sale	Haley Patrick J. EVP, Commercial Officer	10,000 -3.6% 23.00 230,000 USD	10,000 -3.6%	23.00	230,000 USD
2022-04-04	2022-03-31	PS Planned sale	Haley Patrick J. EVP, Commercial Officer	10,000 -3.6% 22.43 224,300 USD	10,000 -3.6%	22.43	224,300 USD
2022-03-30	2022-03-29	PS Planned sale	Hessekiel Jeffrey EVP, General Counsel & Sec Officer	13,283 -2.1% 22.00 292,226 USD	13,283 -2.1%	22.00	292,226 USD
2022-03-30	2022-03-28	PS Planned sale	Hessekiel Jeffrey EVP, General Counsel & Sec Officer	4,717 -0.8% 22.00 103,774 USD	4,717 -0.8%	22.00	103,774 USD
2022-03-03	2022-03-01	PS Planned sale	Garber Alan M Non-Executive Director	21,301 -40.4% 21.00 447,321 USD	21,301 -40.4%	21.00	447,321 USD
2022-02-28	2022-02-25	S Sale	Haley Patrick J. EVP, Commercial Officer	31,238 -13.6% 19.53 610,078 USD	31,238 -13.6%	19.53	610,078 USD
2022-02-28	2022-02-24	PS Planned sale	Hessekiel Jeffrey EVP and General Counsel Officer	18,000 -3.1% 20.00 360,000 USD	18,000 -3.1%	20.00	360,000 USD
2022-02-24	2022-02-22	S Sale	PAPADOPOULOS STELIOS Non-Executive Director	84,515 -6.5% 19.56 1,653,113 USD	84,515 -6.5%	19.56	1,653,113 USD
2022-02-24	2022-02-22	S Sale	FELDBAUM CARL B Non-Executive Director	20,000 -70.1% 19.49 389,800 USD	20,000 -70.1%	19.49	389,800 USD
2022-02-04	2022-02-03	PS Planned sale	Haley Patrick J. EVP, Commercial Officer	60,000 -19.7% 17.91 1,074,600 USD	60,000 -19.7%	17.91	1,074,600 USD
2021-12-17	2021-12-15	PS Planned sale	Lamb Peter EVP, Scientific Strategy & CSO Officer	47,500 -11.6% 17.44 828,400 USD	47,500 -11.6%	17.44	828,400 USD
2021-11-26	2021-11-24	S Sale	Haley Patrick J. EVP, Commercial Officer	17,236 -6.8% 17.25 297,321 USD	17,236 -6.8%	17.25	297,321 USD
2021-11-23	2021-11-19	S Sale	FELDBAUM CARL B Non-Executive Director	20,000 -70.1% 17.62 352,400 USD	20,000 -70.1%	17.62	352,400 USD
2021-11-17	2021-11-15	PS Planned sale	Lamb Peter EVP, Scientific Strategy & CSO Officer	47,500 -10.4% 18.09 859,275 USD	47,500 -10.4%	18.09	859,275 USD
2021-11-03	2021-11-01	PS Planned sale	Hessekiel Jeffrey EVP and General Counsel Officer	5,117 -0.8% 22.03 112,728 USD	5,117 -0.8%	22.03	112,728 USD
2021-10-15	2021-10-15	PS Planned sale	Hessekiel Jeffrey EVP and General Counsel Officer	12,883 -2.0% 22.02 283,684 USD	12,883 -2.0%	22.02	283,684 USD
2021-10-15	2021-10-15	PS Planned sale	Lamb Peter EVP, Scientific Strategy & CSO Officer	47,500 -10.4% 21.92 1,041,200 USD	47,500 -10.4%	21.92	1,041,200 USD
2021-09-17	2021-09-16	PS Planned sale	Haley Patrick J. EVP, Commercial Officer	25,000 -8.2% 20.36 509,000 USD	25,000 -8.2%	20.36	509,000 USD
2021-09-17	2021-09-15	PS Planned sale	Lamb Peter EVP, Scientific Strategy & CSO Officer	47,500 -10.9% 20.46 971,850 USD	47,500 -10.9%	20.46	971,850 USD
2021-06-22	2021-06-17	PS Planned sale	Lamb Peter EVP, Scientific Strategy & CSO Officer	60,000 -13.3% 22.18 1,330,800 USD	60,000 -13.3%	22.18	1,330,800 USD
2021-05-18	2021-05-18	S Sale	Haley Patrick J. EVP, Commercial Officer	14,593 -4.9% 24.73 360,885 USD	14,593 -4.9%	24.73	360,885 USD
2022-11-17	2021-05-17	PS Planned sale	Hessekiel Jeffrey EVP, General Counsel & Sec Officer	18,000 -2.9% 25.39 457,020 USD	18,000 -2.9%	25.39	457,020 USD
2021-05-17	2021-05-14	S Sale	MARCHESI VINCENT T Non-Executive Director	40,000 -37.7% 25.04 1,001,600 USD	40,000 -37.7%	25.04	1,001,600 USD
2021-05-14	2021-05-13	PS Planned sale	Schwab Gisela Pres, Prod Dev & Med Aff & CMO Officer	100,000 -14.0% 25.38 2,538,000 USD	100,000 -14.0%	25.38	2,538,000 USD
2021-05-17	2021-05-11	S Sale	Freire Maria C Non-Executive Director	8,275 -20.6% 25.01 206,958 USD	8,275 -20.6%	25.01	206,958 USD
2021-05-13	2021-05-11	S Sale	PAPADOPOULOS STELIOS Non-Executive Director	5,473 -0.4% 25.01 136,880 USD	5,473 -0.4%	25.01	136,880 USD
2021-05-13	2021-05-11	S Sale	PAPADOPOULOS STELIOS Non-Executive Director	5,075 -0.4% 25.00 126,875 USD	5,075 -0.4%	25.00	126,875 USD
2021-05-13	2021-05-11	S Sale	PAPADOPOULOS STELIOS Non-Executive Director	10,222 -0.8% 24.95 255,039 USD	10,222 -0.8%	24.95	255,039 USD
2021-04-28	2021-04-26	PS Planned sale	Schwab Gisela Pres, Prod Dev & Med Aff & CMO Officer	50,000 -7.5% 25.00 1,250,000 USD	50,000 -7.5%	25.00	1,250,000 USD
2021-04-28	2021-04-26	PS Planned sale	Hessekiel Jeffrey EVP and General Counsel Officer	18,000 -2.8% 25.03 450,540 USD	18,000 -2.8%	25.03	450,540 USD
2021-04-02	2021-04-01	PS Planned sale	Schwab Gisela Pres, Prod Dev & Med Aff & CMO Officer	50,000 -7.5% 23.00 1,150,000 USD	50,000 -7.5%	23.00	1,150,000 USD
2021-04-02	2021-04-01	PS Planned sale	Lamb Peter EVP, Scientific Strategy & CSO Officer	60,000 -13.3% 22.96 1,377,600 USD	60,000 -13.3%	22.96	1,377,600 USD
2021-03-17	2021-03-15	PS Planned sale	Garber Alan M Non-Executive Director	40,000 -75.9% 23.60 944,000 USD	40,000 -75.9%	23.60	944,000 USD
2021-03-03	2021-03-01	PS Planned sale	Lamb Peter EVP, Scientific Strategy & CSO Officer	65,000 -16.0% 22.11 1,437,150 USD	65,000 -16.0%	22.11	1,437,150 USD
2021-02-26	2021-02-24	S Sale	COHEN CHARLES Non-Executive Director	40,000 -18.1% 22.69 907,600 USD	40,000 -18.1%	22.69	907,600 USD
2021-02-24	2021-02-23	S Sale	WILLSEY LANCE Non-Executive Director	800 -0.2% 22.34 17,872 USD	800 -0.2%	22.34	17,872 USD
2021-02-24	2021-02-23	S Sale	WILLSEY LANCE Non-Executive Director	39,200 -8.4% 21.92 859,264 USD	39,200 -8.4%	21.92	859,264 USD
2021-02-24	2021-02-22	S Sale	MARCHESI VINCENT T Non-Executive Director	24,097 -26.7% 22.29 537,122 USD	24,097 -26.7%	22.29	537,122 USD
2021-02-19	2021-02-18	S Sale	Schwab Gisela Pres, Prod Dev & Med Aff & CMO Officer	50,000 -8.5% 22.35 1,117,500 USD	50,000 -8.5%	22.35	1,117,500 USD
2021-02-19	2021-02-17	S Sale	Schwab Gisela Pres, Prod Dev & Med Aff & CMO Officer	50,000 -8.5% 22.50 1,125,000 USD	50,000 -8.5%	22.50	1,125,000 USD
2021-02-24	2021-02-16	S Sale	WILLSEY LANCE Non-Executive Director	50,000 -10.5% 21.90 1,095,000 USD	50,000 -10.5%	21.90	1,095,000 USD
2021-02-17	2021-02-16	S Sale	FELDBAUM CARL B Non-Executive Director	20,000 -70.1% 21.96 439,200 USD	20,000 -70.1%	21.96	439,200 USD
2021-02-17	2021-02-12	S Sale	Haley Patrick J. EVP, Commercial Officer	45,000 -15.4% 21.57 970,650 USD	45,000 -15.4%	21.57	970,650 USD
2021-02-03	2021-02-01	PS Planned sale	Lamb Peter EVP, Scientific Strategy & CSO Officer	65,000 -18.7% 22.08 1,435,200 USD	65,000 -18.7%	22.08	1,435,200 USD